Dale Pfost
Biotechnology Entrepeneur, Executive and Board Member
United States
Overview
Work Experience
Co-Chairman of the Board
2024 - Current
Board Member
2018
AxoSim is an operator of a biomimetic neuroscience discovery platform used to develop a 3D cell-based platform.
Raised $14,189,233.00 from New Orleans BioFund.
Board Member
2021
board member
2009 - 2024
http://www.jmbcompanies.com
Chief Executive Officer and Chairman of the Board
2021 - 2023
Chemomab is a clinical stage public company developing innovative treatments for patients with diseases stemming from inflammation and fibrosis
Business Owner
2010 - 2021
Chief Executive Officer and Chairman of the Board
2019 - 2021
About Lodo Therapeutics Lodo discovers and develops novel therapeutics addressing undruggable targets by applying its proprietary platform to tap the vast collections of undiscovered molecules encoded in environmental microbial DNA. These evolutionarily optimized leads include structurally diverse molecules with drug-like properties that have been largely inaccessible until now. The Lodo platform leverages breakthroughs in next-generation sequencing, artificial intelligence/machine learning and synthetic biology to increase speed and efficiency by orders of magnitude. Following successful initial collaborations with two global partners, Lodo is developing an internal pipeline of oncology drugs and expanding its partnering activities in a range of indications. Lodo is an Accelerator Life Science Partners-backed entity headquartered in New York City. For more information, visit lodotherapeutics.com
Acting CEO
2016 - 2020
MicroBiome Therapeutics (MBT) is an evidenced-based life-sciences company focusing on the use of natural food extracts as next-generation GI microbiome modulators for health. MBT has recently launched BiomeBliss, a clinically-tested prebiotic drink, which acts as a diet aid by naturally helping the activity of the GI microbiome. corporate: mbiome.com product: biomebliss.com
General Partner
2011 - 2019
Advent Life Sciences LLP is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across Europe and the USA. We invest predominantly in early and mid-stage life sciences companies in the UK, Europe and the US. We seek to back truly innovative companies that have a first-in-class or best-in-class approach, and are looking for a well-connected partner on the road to success. Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.
CEO -- remained as board member to Q1 2020
2009 - 2011
MicroBiome Therapeutics (previously known as NuMe Health) is a clinical stage biotechnology company focusing on using insights into the human microbiome for managing prediabetes with microbiome modulators including novel pharmaceuticals and medical foods
Venture Partner
2010 - 2010
Venture Capital in Life Sciences